The Clinical Core will provide the clinical trial infrastructure to support the clinical trial and related translational research that is generated by the four projects that constitute this SPORE application. The components of the Clinical Core leverage the extensive resources and expertise at MD Anderson in clinical and translational research. As the research efforts proposed in the current application represent extensions and expansions of ongoing efforts, the Clinical Core will continue to provide the support and expertise to develop and manage the highly innovative clinical trials that develop from the proposed research efforts. Additionally, recognizing that the scope of clinical trials may encompass from early stage (proof-of principle) studies examining drug/agent delivery and tissue-based efficacy (i.e. pharmacodynamics) to larger, randomized multicenter clinical trials, we have developed a robust web-based clinical trials management software package, the Data Management Initiative (DMI). This system supports state-of-the art tracking of all critical elements of the clinical trial including patient outcomes, adverse events and drug dosing. It contains internal auditing functions thereby limiting resource consuming queries. Furthermore, the DMI has been approved by the FDA for studies containing IND agents and is also approved for registration clinical trials. The Clinical Core will support the specific SPORE projects as described: Project 1: A Phase l/ll study combining the Delta-24 oncolytic virus with temozolomide. Early phase study of evaluating mesenchymal stem cell mediated delivery of Delta-24 into human glioblastoma. Project 2: A Phase I study of combination signal transduction agents followed by a 2-stage multi-arm Bayesian based Adaptive Selection Design clinical trial to test preclinical developed drug combinations. Project 3: No direct Clinical Core support needed for these clinical-molecular studies using outcomes and molecular profiles from large clinical trials. Project 4: A Phase I clinical trial of WPI 066 an oral STAT3 inhibitor with an arm that will evaluate treatment delivery and impact on molecular targets (pharmacokinetics and pharmacodynamics).
The Clinical Core will provide the clinical trials infrastructure to enable the innovative clinical studies that are developed within each of the SPORE projects to be completed with the highest level of oversight and data quality. The Clinical Core has developed resources to support early stage studies that examine treatment effects on the tumor to large scale multi-center studies.
|Gressot, Loyola V; Doucette, Tiffany A; Yang, Yuhui et al. (2015) Signal transducer and activator of transcription 5b drives malignant progression in a PDGFB-dependent proneural glioma model by suppressing apoptosis. Int J Cancer 136:2047-54|
|Chen, James C; Alvarez, Mariano J; Talos, Flaminia et al. (2014) Identification of causal genetic drivers of human disease through systems-level analysis of regulatory networks. Cell 159:402-14|
|Schrand, Brett; Berezhnoy, Alexey; Brenneman, Randall et al. (2014) Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy. Cancer Immunol Res 2:867-77|
|Lang, Frederick F; Barker 2nd, Fred G (2014) A history of the AANS/CNS Section on Tumors Biennial Satellite Symposium. J Neurooncol 119:593-600|
|Olar, Adriana; Aldape, Kenneth D (2014) Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol 232:165-77|
|Singh, Mamata; Leasure, Justin M; Chronowski, Christopher et al. (2014) FANCD2 is a potential therapeutic target and biomarker in alveolar rhabdomyosarcoma harboring the PAX3-FOXO1 fusion gene. Clin Cancer Res 20:3884-95|
|Congdon, Kendra L; Gedeon, Patrick C; Suryadevara, Carter M et al. (2014) Epidermal growth factor receptor and variant III targeted immunotherapy. Neuro Oncol 16 Suppl 8:viii20-5|
|Conrad, Charles A; Fueyo, Juan; Gomez-Manzano, Candelaria (2014) Intratumoral heterogeneity and intraclonal plasticity: from warburg to oxygen and back again. Neuro Oncol 16:1025-6|
|Zhao, Jun; Wallace, Michael; Melancon, Marites P (2014) Cancer theranostics with gold nanoshells. Nanomedicine (Lond) 9:2041-57|
|Jiang, Hong; Clise-Dwyer, Karen; Ruisaard, Kathryn E et al. (2014) Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model. PLoS One 9:e97407|
Showing the most recent 10 out of 70 publications